Search Result

Results for "

B13

" in MedChemExpress (MCE) Product Catalog:

By Targets:	17β-HSD (115) Acyltransferase (1) DNA/RNA Synthesis (1) E3 Ligase Ligand-Linker Conjugates (1) Endogenous Metabolite (7) ERK (1) Estrogen Receptor/ERR (1) Fungal (2) FXR (2) Herbicide (1) iGluR (2) Interleukin Related (2) Isotope-Labeled Compounds (6) Ligands for E3 Ligase (1) Ligands for Target Protein for PROTAC (1) MicroRNA (8) Nucleoside Antimetabolite/Analog (5) OAT (1) Orexin Receptor (OX Receptor) (2) Parasite (1) PPAR (1) PROTAC Linkers (1) PROTACs (1) Reactive Oxygen Species (ROS) (1) Reference Standards (2) Small Interfering RNA (siRNA) (4) STAT (1) Toll-like Receptor (TLR) (1)
By Research Areas:	Cancer (20) Cardiovascular Disease (2) Infection (4) Inflammation/Immunology (5) Metabolic Disease (117) Neurological Disease (4)
Oligonucleotides:	miRNA mimics (2) miRNA antagomirs (2) miRNA agomirs (2) MicroRNAs (8) Rat Pre-designed siRNA Sets (1) miRNA inhibitors (2) Mouse Pre-designed siRNA Sets (1) siRNA drugs (3) Human Pre-designed siRNA Sets (2) siRNAs (8)

149

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0157

Orotic acid 3 Publications Verification 6-Carboxyuracil; Vitamin B13	Nucleoside Antimetabolite/Analog Endogenous Metabolite	Metabolic Disease
Orotic acid (6-Carboxyuracil), a precursor in biosynthesis of pyrimidine nucleotides and RNA, is released from the mitochondrial dihydroorotate dehydrogenase (DHODH) for conversion to UMP by the cytoplasmic UMP synthase enzyme. Orotic acid is a marker for measurement in routine newborn screening for urea cycle disorders. Orotic acid can induce hepatic steatosis and hepatomegaly in rats .

HY-175465

SMI-10B13	Interleukin Related STAT	Cancer
SMI-10B13 is an Oncostatin M (OSM) inhibitor with a K_D of 6.6 μM. SMI-10B13 inhibits OSM-mediated STAT3 phosphorylation in T47D and MCF-7 cell lines (IC₅₀ = 136 and 164 nM, respectively). SMI-10B13 shows anti-tumor effect in human breast cancer mice models .

HY-124962

D-NMAPPD 1 Publications Verification (1R,2R)-B13	iGluR	Neurological Disease Cancer
D-NMAPPD ((1R,2R)-B13) is an acid ceramidase inhibitor. D-NMAPPD regulates NMDA receptor properties by enhancing endogenous production of ceramides. D-NMAPPD has anticancer effecs .

HY-N0157R

Orotic acid (Standard) 6-Carboxyuracil (Standard); Vitamin B13 (Standard)	Reference Standards Nucleoside Antimetabolite/Analog Endogenous Metabolite	Metabolic Disease
Orotic acid (Standard) is the analytical standard of Orotic acid. This product is intended for research and analytical applications. Orotic acid (6-Carboxyuracil), a precursor in biosynthesis of pyrimidine nucleotides and RNA, is released from the mitochondrial dihydroorotate dehydrogenase (DHODH) for conversion to UMP by the cytoplasmic UMP synthase enzyme. Orotic acid is a marker for measurement in routine newborn screening for urea cycle disorders. Orotic acid can induce hepatic steatosis and hepatomegaly in rats .

HY-N0157A

Orotic acid zinc 3 Publications Verification 6-Carboxyuracil zinc; Vitamin B13 zinc	Nucleoside Antimetabolite/Analog Endogenous Metabolite	Metabolic Disease
Orotic acid (zinc), a precursor in biosynthesis of pyrimidine nucleotides and RNA, is released from the mitochondrial dihydroorotate dehydrogenase (DHODH) for conversion to UMP by the cytoplasmic UMP synthase enzyme. Orotic acid (zinc) is a marker for measurement in routine newborn screening for urea cycle disorders. Orotic acid (zinc) can induce hepatic steatosis and hepatomegaly in rats .

HY-N0157C

Orotic acid potassium 3 Publications Verification 6-Carboxyuracil potassium; Vitamin B13 potassium	Endogenous Metabolite DNA/RNA Synthesis	Metabolic Disease
Orotic acid potassium (Vitamin B13 potassium) is a precursor of pyrimidine bases and is involved in the synthesis of DNA and RNA. Orotic acid potassium stimulates the growth of animals, plants and microorganisms, participates in carbohydrate metabolism, and is necessary for the growth and life activities of organisms. Orotic acid potassium is a measurement indicator in routine newborn screening for urea cycle abnormalities. Orotic acid potassium can cause hepatic steatosis and hepatomegaly in rats .

HY-128145

HSD17B13-IN-41	17β-HSD	Metabolic Disease
HSD17B13-IN-41 (Compound C) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-41 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH .

HY-174388

Antifungal agent 134	Fungal Herbicide Reactive Oxygen Species (ROS)	Infection
Antifungal agent 134 (Compound B13) is an antifungal agent with EC₅₀s of 3.24, 1.89, 1.70, 0.36, 4.27, and 1.50 μg/mL for Botrytis cinerea, Alternaria solani, Fusarium graminearum, Rhizoctonia solani, Colletotrichum orbiculare, and Alternaria alternata, respectively. Antifungal agent 134 can disrupt the cell membrane and mitochondria of the hyphae, leading to significant ROS accumulation. Antifungal agent 134 also has significant herbicidal activities against field weeds, such as Amaranthus retroflexus L and Abutilon theophrasti Medicus. Antifungal agent 134 can be used for crop diseases and field weeds research .

HY-174133

HSD17B13-IN-104	17β-HSD	Metabolic Disease Inflammation/Immunology
HSD17B13-IN-104 (Compound 32) is an orally active, highly potent and selective *HSD17B13* inhibitor (IC₅₀=2.5 nM). HSD17B13-IN-104 regulates hepatic lipid metabolism by inhibiting the SREBP-1c/FAS pathway. HSD17B13-IN-104 blocks HSD17B13 enzymatic activity to improve hepatic lipid accumulation. HSD17B13-IN-104 is promising for research of metabolic dysfunction-associated steatohepatitis .

HY-161227

HSD17B13-IN-43	17β-HSD	Metabolic Disease Inflammation/Immunology
HSD17B13-IN-43 is a selective inhibitor of *HSD17B13* that competitively blocks the activity of this enzyme. HSD17B13-IN-43 exhibits an IC₅₀ ≤ 0.1 µM in in vitro assays. HSD17B13-IN-43 can be used in studies of non-alcoholic steatohepatitis, fatty liver disease and hepatic fibrosis .

HY-161979

HSD17B13-IN-103	17β-HSD	Cancer
HSD17B13-IN-103 (Compound 44) is a *HSD17B13* inhibitor. HSD17B13-IN-103 can be used in the study of non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) .

HY-156735

HSD17B13-IN-2	17β-HSD	Cancer
HSD17B13-IN-2 is an *HSD17B13* inhibitor with human IC₅₀ values of 0.18 μM (with β-estradiol as substrate) and 0.25 μM (with Leukotriene B4 as substrate), and it exhibits selectivity for human HSD17B11. HSD17B13-IN-2 binds to the active site of *HSD17B13* in an NAD ⁺-dependent manner, interacts with the bound NAD ⁺ cofactor, and stabilizes human *HSD17B13* protein to prevent its aggregation. HSD17B13-IN-2 reduces the conversion of β-estradiol to estrone in cellular assays. HSD17B13-IN-2 can be used in studies related to nonalcoholic fatty liver disease .

HY-157665

HSD17B13-IN-39	17β-HSD	Metabolic Disease
HSD17B13-IN-39 (Compound A) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-39 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH .

HY-157630

HSD17B13-IN-10	17β-HSD	Metabolic Disease
HSD17B13-IN-10 (Compound 464) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of 0.01 μM. HSD17B13-IN-10 can be used in the research of liver diseases .

HY-157664

HSD17B13-IN-38	17β-HSD	Metabolic Disease
HSD17B13-IN-38 (Compound D) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-38 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH .

HY-157708

HSD17B13-IN-67	17β-HSD	Metabolic Disease
HSD17B13-IN-67 (Compound 677) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of < 0.1 μM for estradiol. HSD17B13-IN-67 can be used for research on liver diseases or metabolic disorders .

HY-157722

HSD17B13-IN-73	17β-HSD	Metabolic Disease
HSD17B13-IN-73 (Compound 85) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of < 0.1 μM for estradiol. HSD17B13-IN-73 can be used for research on liver diseases or metabolic disorders .

HY-157717

HSD17B13-IN-70	17β-HSD	Metabolic Disease
HSD17B13-IN-70 (Compound 39) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of < 0.1 μM for estradiol. HSD17B13-IN-70 can be used for research on liver diseases or metabolic disorders .

HY-157674

HSD17B13-IN-46	17β-HSD	Metabolic Disease
HSD17B13-IN-46 (Compound 351) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of < 0.1 μM for estradiol. HSD17B13-IN-46 can be used for research on liver diseases or metabolic disorders .

HY-157726

HSD17B13-IN-77	17β-HSD	Metabolic Disease
HSD17B13-IN-77 (Compound 808) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of < 0.1 μM for estradiol. HSD17B13-IN-77 can be used for research on liver diseases or metabolic disorders .

HY-157650

HSD17B13-IN-20	17β-HSD	Metabolic Disease
HSD17B13-IN-38 (Compound 18.02) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-38 can be used in the research of liver diseases such as hepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma .

HY-157710

HSD17B13-IN-68	17β-HSD	Metabolic Disease
HSD17B13-IN-68 (Compound 16) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of < 0.1 μM for estradiol. HSD17B13-IN-68 can be used for research on liver diseases or metabolic disorders .

HY-157676

HSD17B13-IN-47	17β-HSD	Metabolic Disease
HSD17B13-IN-47 (Compound 500) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of < 0.1 μM for estradiol. HSD17B13-IN-47 can be used for research on liver diseases or metabolic disorders .

HY-157720

HSD17B13-IN-72	17β-HSD	Metabolic Disease
HSD17B13-IN-72 (Compound 62) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of < 0.1 μM for estradiol. HSD17B13-IN-72 can be used for research on liver diseases or metabolic disorders .

HY-157667

HSD17B13-IN-44	17β-HSD	Metabolic Disease
HSD17B13-IN-44 (Compound 23) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of < 0.1 μM for estradiol. HSD17B13-IN-44 can be used for research on liver diseases or metabolic disorders .

HY-157671

HSD17B13-IN-45	17β-HSD	Metabolic Disease
HSD17B13-IN-45 (Compound 195) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of < 0.1 μM for estradiol. HSD17B13-IN-45 can be used for research on liver diseases or metabolic disorders .

HY-157653

HSD17B13-IN-22	17β-HSD	Metabolic Disease
HSD17B13-IN-22 (Compound 18.03) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-22 can be used in the research of liver diseases such as hepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma .

HY-157615

HSD17B13-IN-6	17β-HSD	Metabolic Disease
HSD17B13-IN-6(Compound 475) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of 0.01 μM. HSD17B13-IN-6can be used in the research of liver diseases .

HY-157724

HSD17B13-IN-76	17β-HSD	Metabolic Disease
HSD17B13-IN-76 (Compound 773) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of < 0.1 μM for estradiol. HSD17B13-IN-76 can be used for research on liver diseases or metabolic disorders .

HY-157723

HSD17B13-IN-74	17β-HSD	Metabolic Disease
HSD17B13-IN-74 (Compound 760) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of < 0.1 μM for estradiol. HSD17B13-IN-74 can be used for research on liver diseases or metabolic disorders .

HY-157632

HSD17B13-IN-13	17β-HSD	Metabolic Disease
HSD17B13-IN-13 (Compound 5) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of < 0.1 μM for estradiol. HSD17B13-IN-13 can be used in the research of liver diseases, such as NAFLD .

HY-157654

HSD17B13-IN-26	17β-HSD	Metabolic Disease
HSD17B13-IN-26 (Compound 18.04) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-26 can be used in the research of liver diseases such as hepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma .

HY-161211

HSD17B13-IN-7	17β-HSD iGluR	Metabolic Disease
HSD17B13-IN-7 (compound 1), a fluorophenol-containing compound, is a potent *HSD17B13* inhibitor with IC₅₀s of 0.18 μM and 0.25 μM β-estradiol and Leukotriene B4 as substrates, respectively. HSD17B13-IN-7 is a potent N-methyl-D-aspartate (NMDA) NR2B receptor antagonist. HSD17B13-IN-7 has the potential for non-alcoholic fatty liver disease research .

HY-161278

HSD17B13-IN-102	17β-HSD	Cancer
HSD17B13-IN-100 (compound 37) is an inhibitor of *HSD17B13* and has IC₅₀ with Estradiol ＜0.1 μM .

HY-161277

HSD17B13-IN-100	17β-HSD	Cancer
HSD17B13-IN-100 (compound 34) is an inhibitor of *HSD17B13* and has IC₅₀ with estradiol ＜0.1 μM .

HY-179015

HSD17B13/PPAR modulator-1	17β-HSD PPAR	Metabolic Disease Inflammation/Immunology
HSD17B13/PPAR modulator-1 (Compound 17) is a *HSD17B13/PPAR* multitarget modulator. HSD17B13/PPAR modulator-1 is an inhibitor of *HSD17B13, with its IC₅₀* value being 0.91 μM. HSD17B13/PPAR modulator-1 is a PPAR agonist, with the EC₅₀ values for PPARα, PPARδ, and PPARγ being 1.55, 0.12, and 0.01 μM respectively. HSD17B13/PPAR modulator-1 can significantly improve liver function, regulate lipid metabolism, alleviate fibrosis, and exert antioxidant and anti-inflammatory effects in the model of metabolic dysfunction-related steatohepatitis (MASH). HSD17B13/PPAR modulator-1 can be used for the study of MASH .

HY-157627

HSD17B13-IN-9	17β-HSD	Metabolic Disease
HSD17B13-IN-9 (252) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC₅₀ of 0.01 μM for 50 nM HSD17B13. Used in NAFLD (Nonalcoholic fatty liver diseases) research .

HY-148926

HSD17B13-IN-1	17β-HSD	Metabolic Disease
HSD17B13-IN-1 (compound 2) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC₅₀ of ＜ 0.1 μM? estradiol? as substrates. HSD17B13-IN-1? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .

HY-161226

HSD17B13-IN-42	17β-HSD	Metabolic Disease
HSD17B13-IN-42 (compound 10)? is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC₅₀ of ＜ 0.1 μM? estradiol? as substrates. HSD17B13-IN-42? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .

HY-163244

HSD17B13-IN-30	17β-HSD	Metabolic Disease
HSD17B13-IN-30 (compound 64) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC₅₀ of ＜ 0.1 μM? estradiol? as substrates. HSD17B13-IN-30? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .

HY-163247

HSD17B13-IN-35	17β-HSD	Metabolic Disease
HSD17B13-IN-35 (compound 76) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC₅₀ of ＜ 0.1 μM? estradiol? as substrates. HSD17B13-IN-35? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .

HY-163242

HSD17B13-IN-28	17β-HSD	Metabolic Disease
HSD17B13-IN-28 (compound? 47) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC₅₀ of ＜ 0.1 μM? estradiol? as substrates. HSD17B13-IN-28? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .

HY-161225

HSD17B13-IN-40	17β-HSD	Metabolic Disease
HSD17B13-IN-40 (compound 6) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC₅₀ of ＜ 0.1 μM? estradiol? as substrates. HSD17B13-IN-40? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .

HY-162278

HSD17B13-IN-101	17β-HSD	Metabolic Disease
HSD17B13-IN-101 is a selective inhibitor of 17 β-hydroxysteroid dehydrogenase (HSD17B13), and its IC₅₀ value for Estradiol is <0.1 μM. HSD17B13-IN-101 can be used in the study of nonalcoholic fatty liver disease (NAFLD) (WO2023146897A1; compound 94) .

HY-157663

HSD17B13-IN-36	17β-HSD	Metabolic Disease
HSD17B13-IN-36 (compound 116) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC₅₀ of ＜ 0.1 μM? estradiol? as substrates. HSD17B13-IN-36? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .

HY-157613

HSD17B13-IN-5	17β-HSD	Metabolic Disease
HSD17B13-IN-5 (Compound 96) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with a K_i value of ≤ 50 nM for the estradiol substrate LCMS. HSD17B13-IN-5 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI) .

HY-157601

HSD17B13-IN-4	17β-HSD	Metabolic Disease
HSD17B13-IN-4 (Compound 95) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with a K_i value of ≤ 50 nM for the estradiol substrate LCMS. HSD17B13-IN-4 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI) .

HY-163243

HSD17B13-IN-29	17β-HSD	Metabolic Disease
HSD17B13-IN-29 (Compound 53) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-29 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HY-163249

HSD17B13-IN-49	17β-HSD	Metabolic Disease
HSD17B13-IN-49 (Compound 81) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-49 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HY-161229

HSD17B13-IN-69	17β-HSD	Metabolic Disease
HSD17B13-IN-69 (Compound 11) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-69 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

Cat. No.	Product Name	Type

HY-N0157C

Orotic acid potassium

3 Publications Verification

6-Carboxyuracil potassium; Vitamin B13 potassium

Biochemical Assay Reagents

Orotic acid potassium (Vitamin B13 potassium) is a precursor of pyrimidine bases and is involved in the synthesis of DNA and RNA. Orotic acid potassium stimulates the growth of animals, plants and microorganisms, participates in carbohydrate metabolism, and is necessary for the growth and life activities of organisms. Orotic acid potassium is a measurement indicator in routine newborn screening for urea cycle abnormalities. Orotic acid potassium can cause hepatic steatosis and hepatomegaly in rats .

Cat. No.	Product Name	Target	Research Area

HY-P1339AS1

Orexin B, human-13C18,15N3 TFA Human orexin B-13C18,15N3 TFA	Isotope-Labeled Compounds Orexin Receptor (OX Receptor)	Cardiovascular Disease Neurological Disease
Orexin B, human- ¹³C₁₈, ¹⁵N₃ (Human orexin B- ¹³C₁₈, ¹⁵N₃) TFA is the ¹³C- and ¹⁵N-labeled Orexin B, human (HY-P1339). Orexin B, human is the agonist for Orexin Receptor, with K_is of 420 nM and 36 nM for OX1 and OX2. Orexin B, human participates in the regulation of appetite, wakefulness, cardiovascular function and neuroendocrine .

HY-P1339AS

Orexin B, human-13C6,15N TFA Human orexin B-13C6,15N TFA	Isotope-Labeled Compounds Orexin Receptor (OX Receptor)	Cardiovascular Disease Neurological Disease
Orexin B, human- ¹³C₆, ¹⁵N (Human orexin B- ¹³C₆, ¹⁵N) TFA is the ¹³C- and ¹⁵N-labeled Orexin B, human (HY-P1339). Orexin B, human is the agonist for Orexin Receptor, with K_is of 420 nM and 36 nM for OX1 and OX2. Orexin B, human participates in the regulation of appetite, wakefulness, cardiovascular function and neuroendocrine .

Cat. No.	Product Name	Target	Research Area	Image

HY-P990228

Anti-Mouse IL-10R/CD210 Antibody (1B1.3A)	Interleukin Related Parasite Fungal	Infection Metabolic Disease
Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) is a rat-derived IgG1 κ type antibody inhibitor, targeting to mouse IL-10R/CD210. Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) blocks IL-10R signaling. Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) can be used for the researches of cancer, infection and metabolic disease, such as diabetes and malaria .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0157

Orotic acid 3 Publications Verification 6-Carboxyuracil; Vitamin B13	Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Disease markers Endocrine diseases Metabolic Disease Nervous System Disorder Endogenous metabolite Disease Research Fields	Nucleoside Antimetabolite/Analog Endogenous Metabolite
Orotic acid (6-Carboxyuracil), a precursor in biosynthesis of pyrimidine nucleotides and RNA, is released from the mitochondrial dihydroorotate dehydrogenase (DHODH) for conversion to UMP by the cytoplasmic UMP synthase enzyme. Orotic acid is a marker for measurement in routine newborn screening for urea cycle disorders. Orotic acid can induce hepatic steatosis and hepatomegaly in rats .

HY-N0157R

Orotic acid (Standard) 6-Carboxyuracil (Standard); Vitamin B13 (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Disease markers Endocrine diseases Nervous System Disorder Endogenous metabolite	Reference Standards Nucleoside Antimetabolite/Analog Endogenous Metabolite
Orotic acid (Standard) is the analytical standard of Orotic acid. This product is intended for research and analytical applications. Orotic acid (6-Carboxyuracil), a precursor in biosynthesis of pyrimidine nucleotides and RNA, is released from the mitochondrial dihydroorotate dehydrogenase (DHODH) for conversion to UMP by the cytoplasmic UMP synthase enzyme. Orotic acid is a marker for measurement in routine newborn screening for urea cycle disorders. Orotic acid can induce hepatic steatosis and hepatomegaly in rats .

HY-N0157A

Orotic acid zinc 3 Publications Verification 6-Carboxyuracil zinc; Vitamin B13 zinc	Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Nucleoside Antimetabolite/Analog Endogenous Metabolite
Orotic acid (zinc), a precursor in biosynthesis of pyrimidine nucleotides and RNA, is released from the mitochondrial dihydroorotate dehydrogenase (DHODH) for conversion to UMP by the cytoplasmic UMP synthase enzyme. Orotic acid (zinc) is a marker for measurement in routine newborn screening for urea cycle disorders. Orotic acid (zinc) can induce hepatic steatosis and hepatomegaly in rats .

HY-N0157AR

Orotic acid zinc (Standard) 6-Carboxyuracil zinc (Standard); Vitamin B13 zinc (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Nucleoside Antimetabolite/Analog Endogenous Metabolite Reference Standards
Orotic acid (zinc) (Standard) is the analytical standard of Orotic acid (zinc). This product is intended for research and analytical applications. Orotic acid (zinc), a precursor in biosynthesis of pyrimidine nucleotides and RNA, is released from the mitochondrial dihydroorotate dehydrogenase (DHODH) for conversion to UMP by the cytoplasmic UMP synthase enzyme. Orotic acid (zinc) is a marker for measurement in routine newborn screening for urea cycle disorders. Orotic acid (zinc) can induce hepatic steatosis and hepatomegaly in rats .

HY-138142

Euphol acetate	Triterpenes other families Classification of Application Fields Terpenoids Metabolic Disease Plants Disease Research Fields Source Classification	OAT
Euphol acetate is a triterpene that can be isolated from Euphorbia broteri. Euphol acetate is an inhibitor of hepatic transport proteins organic anion-transporting polypeptide 1/3 (OATP1B1/3) .

Cat. No.	Product Name	Chemical Structure

HY-N0157S1

Orotic acid-13C,15N2 monohydrate

Orotic acid- ¹³C, ¹⁵N₂ (monohydrate) is the ¹³C and ¹⁵N labeled Orotic acid . Orotic acid (6-Carboxyuracil), a precursor in biosynthesis of pyrimidine nucleotides and RNA, is released from the mitochondrial dihydroorotate dehydrogenase (DHODH) for conversion to UMP by the cytoplasmic UMP synthase enzyme. Orotic acid is a marker for measurement in routine newborn screening for urea cycle disorders. Orotic acid can induce hepatic steatosis and hepatomegaly in rats .

HY-P1339AS1

Orexin B, human-13C18,15N3 TFA
Orexin B, human- ¹³C₁₈, ¹⁵N₃ (Human orexin B- ¹³C₁₈, ¹⁵N₃) TFA is the ¹³C- and ¹⁵N-labeled Orexin B, human (HY-P1339). Orexin B, human is the agonist for Orexin Receptor, with K_is of 420 nM and 36 nM for OX1 and OX2. Orexin B, human participates in the regulation of appetite, wakefulness, cardiovascular function and neuroendocrine .

HY-163263S1

HSD17B13-IN-80-d2

HSD17B13-IN-80-d₂ (Compound 200) is the the deuterium labeled HSD17B13-IN-80 (HY-163263). HSD17B13-IN-80 is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-80 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HY-163253S

HSD17B13-IN-56-d3
HSD17B13-IN-56-D3 (Compound 169) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-56-D3 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HY-163263S

HSD17B13-IN-80-d3
HSD17B13-IN-80-d3 (179) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC₅₀ of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research .

HY-163259S

HSD17B13-IN-62-d3
HSD17B13-IN-62-d3 (176) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC₅₀ of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research .

HY-W753532

*Bisphenol B-13C12*
Bisphenol B- ¹³C₁₂ is ¹³C labeled Bisphenol B .

HY-N6786S

*Ochratoxin B-13C20*
Ochratoxin B- ¹³C₂₀ is ¹³C-labeled Ochratoxin B (HY-N6786). Ochratoxin B is an orally active secondary metabolite of Aspergillus ochraceus and non-chlorinated analog of the mycotoxin Ochratoxin A. Ochratoxin B reduces the toxic effects of Ochratoxin A (HY-N6788). Ochratoxin B inhibits cell division. Ochratoxin B causes craniofacial malformations in Xenopus laevis embryos .

HY-117313S2

*Fumitremorgin B-13C27*
Fumitremorgin B- ¹³C₂₇ is the ¹³C-labeled Fumitremorgin B (HY-117313). Fumitremorgin B is a tremorgenic mycotoxin. Fumitremorgin B exhibits significant antifungal activities, with MICs of 6.25-50 μg/mL .

HY-N3806S

*Enniatin B-13C33*
Enniatin B- ¹³C₃₃ is the ¹³C-labeled Enniatin B (HY-N3806). Enniatin B is a Fusarium mycotoxin. Enniatin B inhibits acyl-CoA: cholesterol acyltransferase (ACAT) activity with an IC50 of 113 μM in an enzyme assay using rat liver microsomes . Enniatins B decreases the activation of ERK (p44/p42) .

HY-P1339AS

Orexin B, human-13C6,15N TFA
Orexin B, human- ¹³C₆, ¹⁵N (Human orexin B- ¹³C₆, ¹⁵N) TFA is the ¹³C- and ¹⁵N-labeled Orexin B, human (HY-P1339). Orexin B, human is the agonist for Orexin Receptor, with K_is of 420 nM and 36 nM for OX1 and OX2. Orexin B, human participates in the regulation of appetite, wakefulness, cardiovascular function and neuroendocrine .

Host:	Mouse (5) Rabbit (3)
Reactivity:	Human (8) Rat (1) Mouse (1)
Application:	IHC-P (6) ICC/IF (4) IF-Tissue (1) IP (2) WB (2) FC (1) ELISA (1)
Isotype:	IgG (3) IgG1 (5)
Conjugation:	Non-conjugated (8)
Clonality:	Monoclonal (5) Recombinant (2)
Modification:	Unmodified (5)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P88403

	NDUFA5 Antibody (YA8087) B13; CI-13kB; CI-13KD-B; NUFM; UQOR13	ICC/IF	Human
	NDUFA5 Antibody (YA8087) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to NDUFA5.

HY-P88403A

	NDUFA5 Antibody (YA8087)(PBS only) B13; CI-13kB; CI-13KD-B; NUFM; UQOR13	ICC/IF	Human
	NDUFA5 Antibody (YA8087) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to NDUFA5.

HY-P81453

	HOXB13 Antibody (YA1198) HOXB13; Homeobox protein Hox-B13	IHC-P	Human
	HOXB13 Antibody (YA1198) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HOXB13.

HY-P810340

	HOXB13 Antibody (YA9662) Homeobox protein Hox-B13, HOXB13	WB, ICC/IF, IF-Tissue, IHC-P, IP, ELISA	Human
	HOXB13 Antibody (YA9662) is a Mouse-derived and non-conjugated IgG1 Monoclonal antibody, targeting to HOXB13.

HY-P81453A

	HOXB13 Antibody (YA1198)(PBS only) HOXB13; Homeobox protein Hox-B13	IHC-P	Human
	HOXB13 Antibody (YA1198) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HOXB13.

HY-P88313

	HSD17B13 Antibody (YA7997) HMFN0376; NIIL497; SCDR9; SDR16C3	IHC-P	Human
	HSD17B13 Antibody (YA7997) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to HSD17B13.

HY-P88313A

	HSD17B13 Antibody (YA7997)(PBS only) HMFN0376; NIIL497; SCDR9; SDR16C3	IHC-P	Human
	HSD17B13 Antibody (YA7997) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to HSD17B13.

HY-P82685

	DISC1 Antibody (YA2430) C1orf136; DISC1; KIAA0457; RP4-730B13.1; SCZD9	WB, IHC-P, ICC/IF, IP, FC	Human, Mouse, Rat
	DISC1 Antibody (YA2430) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to DISC1.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-164221A

Rapirosiran sodium ALN-HSD sodium		siRNAs siRNA drugs
Rapirosiran sodium is a N-acetylgalactosamine-conjugated small-interfering RNA targeting liver-expressed hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) mRNA. Loss-of-function variants in the HSD17B13 associated with reduced risk of chronic liver disease. Rapirosiran sodium can be used for the study of Non-alcoholic steatohepatitis.

HY-RS17283

Hsd17b13 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Hsd17b13 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Hsd17b13 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-164221

Rapirosiran ALN-HSD; ALN-288996; AD-288996		siRNAs
Rapirosiran is a N-acetylgalactosamine-conjugated small-interfering RNA targeting liver-expressed hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) mRNA. Loss-of-function variants in the HSD17B13 associated with reduced risk of chronic liver disease. Rapirosiran can be used for the study of Non-alcoholic steatohepatitis.

HY-177634

Gatuzosiran		siRNAs siRNA drugs
Gatuzosiran, a siRNA,is a 17-beta-hydroxysteroid dehydrogenase 13 (HSD17B13) synthesis reducer. It is used for the study of fatty liver disease.

HY-177634A

Gatuzosiran sodium		siRNAs siRNA drugs
Gatuzosiran sodium, a siRNA,is a 17-beta-hydroxysteroid dehydrogenase 13 (HSD17B13) synthesis reducer. It is used for the study of fatty liver disease.

HY-RS06393

HSD17B13 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
HSD17B13 Human Pre-designed siRNA Set A contains three designed siRNAs for HSD17B13 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS23738

Hsd17b13 Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Hsd17b13 Rat Pre-designed siRNA Set A contains three designed siRNAs for Hsd17b13 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS09131

NDUFA5 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
NDUFA5 Human Pre-designed siRNA Set A contains three designed siRNAs for NDUFA5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-R00165

hsa-miR-125b-1-3p mimic		MicroRNAs miRNA mimics
hsa-miR-125b-1-3p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

HY-R04364

rno-miR-344b-1-3p mimic		MicroRNAs miRNA mimics
rno-miR-344b-1-3p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

HY-RI00165

hsa-miR-125b-1-3p inhibitor		MicroRNAs miRNA inhibitors
hsa-miR-125b-1-3p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

HY-R04364A

rno-miR-344b-1-3p agomir		MicroRNAs miRNA agomirs
rno-miR-344b-1-3p agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

HY-R00165A

hsa-miR-125b-1-3p agomir		MicroRNAs miRNA agomirs
hsa-miR-125b-1-3p agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

HY-RI00165A

hsa-miR-125b-1-3p antagomir		MicroRNAs miRNA antagomirs
hsa-miR-125b-1-3p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

HY-RI04364

rno-miR-344b-1-3p inhibitor		MicroRNAs miRNA inhibitors
rno-miR-344b-1-3p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

HY-RI04364A

rno-miR-344b-1-3p antagomir		MicroRNAs miRNA antagomirs
rno-miR-344b-1-3p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

B13

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Natural
Products